3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Neoplasm Metastasis
4
Lymphoma
4
Carcinoma, Non-Small-Cell Lung
4
Neuroblastoma
3
Melanoma
3
Lung Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Oligodendroglioma
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Gliosarcoma
2
Glioma
2
Glioblastoma
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Astrocytoma
2
Advanced Malignant Solid Tumor
2
Adenoma, Islet Cell
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Resectable Pancreatic Cancer
1
Interventions
pembrolizumab
12
Radiotherapy
9
avelumab
8
Nivolumab
8
cemiplimab
4
Radiation
4
Ipilimumab
4
poly ICLC
3
atezolizumab
3
Specimen Handling
3
Magnetic Resonance Spectroscopy
3
Etoposide
3
Cyclophosphamide
3
talimogene laherparepvec
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
aldesleukin
2
Interferon-beta
2
Immunoglobulin G
2
Immune Checkpoint Inhibitors
2
Cisplatin
2
Carboplatin
2
Biopsy
2
veliparib
1
vatalanib
1
tremelimumab
1
tocilizumab
1
temsirolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Carcinoma, Merkel Cell
×
Colony-Stimulating Factors
×
Clear all
NCT05269381
2026-03-12
PNeoVCA
Mayo Clinic
Phase 1/2
Recruiting
132 enrolled